Neurology News

CHARLOTTE, N.C. — Study results indicate that better sleep efficiency in patients with fibromyalgia and insomnia may help improve their pain-related disability, according to a poster presented at the SLEEP meeting.

SAN DIEGO — A new neuropsychological test battery may be valuable for assessment of culturally diverse populations if barriers for testing are considered, according to an expert at the Alzheimer’s Association International Conference.

SAN DIEGO — Identifying regions vulnerable to beta-amyloid deposits in younger populations may help predict future accumulation, according to study results presented at the Alzheimer’s Association International Conference.

CHARLOTTE, N.C. — Data from a real-world study revealed that treatment with prescription digital therapeutic Somryst achieved reductions in symptoms of insomnia, anxiety and depression, per a late-breaking poster at the SLEEP meeting.

A consortium led by Weill Cornell Medicine has been awarded a $14.7 million NIH grant for its research center, which focuses on emerging and existing technologies that provide support for older adults with cognitive impairments.

Patients with MS who took diroximel fumarate reported physical benefits, including slowed disease progression and decreased relapses, according to data presented at the Consortium of Multiple Sclerosis Centers annual meeting.

Marinus Pharmaceuticals Inc. announced the Unites States commercial launch of Ztalmy oral suspension for the treatment of seizures associated with CDKL5 deficiency disorder in patients aged 2 years and older.

Quanterix Corp. announced the validation of a laboratory-developed test to quantitatively measure phospho-Tau 181 concentration in plasma to aid in the diagnosis of Alzheimer’s disease.

In patients with primary progressive MS who experience persistent inflammatory activity, disease-modifying therapies were linked to a reduced risk for becoming wheelchair dependent, according to a study in JAMA Neurology.

In this week’s edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more.